Drug Approval | April 26, 2022
ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The product is expected to be available in a week’s time
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
Subscribe To Our Newsletter & Stay Updated
